The Long Run with Luke Timmerman

Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases

The Long Run with Luke Timmerman

Show Notes

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

More from The Long Run with Luke Timmerman

Oct 23, 2026

Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.

Oct 7, 2026

Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.

Sep 23, 2026

Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

Sep 9, 2026

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

Aug 25, 2026

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.

See all episodes →